ORBi: Fievez Virginie - Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination

Reference : Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination


	Document type :	Scientific journals : Article
	Discipline(s) :	Physical, chemical, mathematical & earth Sciences : Chemistry Engineering, computing & technology : Materials science & engineering
	To cite this reference:	http://hdl.handle.net/2268/19919

Title :	Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination
Language :	English
Author, co-author :	Fievez, Virginie [Université catholique de Louvain (UCL) > > Unité de Pharmacie Galénique (Bruxelles) et Laboratoire de Biochimie cellulaire, toxicologique et nutritionnelle (Louvain-la-Neuve) > >]
	Plapied, Laurence [Université catholique de Louvain (UCL),Bruxelles > > Unité de Pharmacie Galénique > >]
	des Rieux, Anne [Université catholique de Louvain (UCL), Bruxelles > Unité de Pharmacie Galénique > > >]
	Pourcelle, Vincent [Université catholique de Louvain (UCL) > > Unité de Chimie Organique et Médicinale > >]
	Freichels, Hélène [University of Liège (ULg) > Department of Chemistry > Center for Education and Research on Macromolecules (CERM) > >]
	Wascotte, Valentine [Université catholique de Louvain (UCL), Bruxelles > > Unité de Pharamcie Galénique > >]
	Vanderhaegen, Marie-Lyse [Université catholique de Louvain (UCL), Bruxelles > > Unité de Pharamcie Galénique > >]
	Jérôme, Christine [University of Liège (ULg) > Department of Chemistry > Center for Education and Research on Macromolecules (CERM) > >]
	Vanderplasschen, Alain [University of Liège (ULg) > Département des Maladies infectieuses et parasitaires > Immunologie et vaccinologie > >]
	Marchand-Brynaert, Jacqueline [Université catholique de Louvain (UCL) > > Unité de Chimie Organique et Médicinale > >]
	Préat, Véronique [Université catholique de Louvain (UCL), Bruxelles > > Unité de Pharmacie Galénique > >]
Publication date :	2009
Journal title :	European Journal of Pharmaceutics & Biopharmaceutics
Publisher :	Elsevier Science
Audience :	International
ISSN :	0939-6411
City :	Amsterdam
Country :	The Netherlands
Keywords :	[en] biomaterial ; nanomedicine ; organic nanoparticle
Abstract :	[en] The presence of RGD on nanoparticles allows the targeting of β1 integrins at the apical surface of human M cells and the enhancement of an immune response after oral immunization. To check the hypothesis that non-peptidic ligands targeting intestinal M cells or APCs would be more efficient for oral immunization than RGD, novel non-peptidic and peptidic analogs (RGD peptidomimitic (RGDp), LDV derivative (LDVd) and LDV peptidomimetic (LDVp)) as well as mannose were grafted on the PEG chain of PCL–PEG and incorporated in PLGA-based nanoparticles. RGD and RGDp significantly increased the transport of nanoparticles across an in vitro model of human M cells as compared to enterocytes. RGD, LDVp, LDVd and mannose enhanced nanoparticle uptake by macrophages in vitro. The intraduodenal immunization with RGDp-, LDVd- or mannose-labeled nanoparticles elicited a higher production of IgG antibodies than the intramuscular injection of free ovalbumin or intraduodenal administration of either non-targeted or RGD-nanoparticles. Targeted formulations were also able to induce a cellular immune response. In conclusion, the in vitro transport of nanoparticles, uptake by macrophages and the immune response were positively influenced by the presence of ligands at the surface of nanoparticles. These targeted-nanoparticles could thus represent a promising delivery system for oral immunization.
Research units :	Center for Education and Research on Macromolecules (CERM)
Funders :	Fonds de la Recherche Scientifique (Communauté française de Belgique) - F.R.S.-FNRS ; Région wallonne : Direction générale des Technologies, de la Recherche et de l'Energie (DGTRE) in the frame of a FIRST EUROPE and VACCINOR (WINNOMAT) projects
Target :	Researchers
Permalink :	http://hdl.handle.net/2268/19919
DOI :	10.1016/j.ejpb.2009.04.009
Other URL :	http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6T6C-4W6Y7YS-2-H&_cdi=5027&_user=532038&_orig=browse&_coverDate=09%2F30%2F2009&_sk=999269998&view=c&wchp=dGLbVtz-zSkzS&md5=f8143a2902f6cb816085317d826026dc&ie=/sdarticle.pdf
	http://www.elsevier.com/wps/find/journaldescription.cws_home/600120/description#description
Mentions required by the publisher for OA :	The authors acknowledge European Journal of Pharmaceutics & Biopharmaceutics (Elsevier) for allowing them to archive this paper.

File(s) associated to this reference

Fulltext file(s):

	File	Commentary	Version	Size	Access
Restricted access	Fievez V 2009 Eur J Pharm Biopharm 10534.pdf		Publisher postprint	547.31 kB	Request copy
Open access	Fievez V 2009 Eur J Pharm Biopharm 10534.pdf		Author postprint	349.45 kB	View/Open

All documents in ORBi are protected by a user license.

Dspace v1.5